BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Antengene Reports Strong H1 2025 Results with Breakthrough Therapy Designation for ATG-022 and Robust Pipeline Progress

The Phase I/II CLINCH study of ATG-022 (CLDN18.2 antibody-drug conjugate) demonstrated promising results, showing robust clinical efficacy and a fav...

August 25, 2025 | Company results

WuXi XDC Delivers 62% Revenue Growth and Record Project Momentum in H1 2025

- Revenue increased by 62.2% YoY to RMB 2,701 million - Gross profit surged by 82.2% YoY to RMB 975 million, with i...

August 19, 2025 | Company results

WuXi Biologics Achieves Fully Automated Continuous Drug Substance Manufacturing at Pilot Scale with WuXiUP™ Platform

Building on its success in developing continuous production at pilot-scale with the WuXiUP™ platform, WuXi Biologics has further enhanced the ...

August 13, 2025 | News

ProBio Launches GMP AAV Manufacturing Services at New Jersey Facility to Accelerate Gene Therapy Development

ProBio, a leading contract development and manufacturing organization (CDMO) specializing in gene and cell therapy, announced the launch of its cGMP Adeno-...

August 12, 2025 | News

PolyActiva Launches U.S. Trial of Glaucoma Implant Following Australia Success

PA5108, a new chemical entity, is an investigational, biodegradable ocular micro implant, designed to deliver sustained intraocular pressure control for ...

August 08, 2025 | News

AGC Biologics Partners with Valneva to Advance Phase II Shigella Vaccine Supply from Heidelberg Site

AGC Biologics, your friendly CDMO expert, announced a development and manufacturing services agreement with specialty vaccine company Valneva SE ...

July 31, 2025 | News

I Peace and Vita Therapeutics Partner to Develop Universal Hypoimmune iPSC Lines for Cell Therapy

Leading GMP cell CDMO I Peace, Inc. specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, announced that the co...

July 11, 2025 | News

WuXi Biologics Launches WuXiHigh™2.0 to Enable Record-Setting High-Concentration Biologic Formulations

The WuXiHigh™2.0 technology platform harnesses proprietary excipient blends and expertise to enable concentrations up to 230 mg/mL It reduces visc...

July 01, 2025 | News

Vetter Breaks Ground on New Clinical Manufacturing Site in Illinois to Expand U.S. Operations

Production site expected to be fully operational by the end of 2029 Modern site with holistic approach for state-of-the-art manufacturing operations Fu...

June 30, 2025 | News

AGC Biologics Launches Cell Therapy Manufacturing Services in Yokohama to Expand Global CDMO Footprint

AGC Biologics, your friendly CDMO expert, will commence cell therapy process development and clinical manufacturing services on July 1, 2025, at AGC Inc....

June 26, 2025 | News

Sanyou Biopharmaceuticals and TransRecoBio Form Strategic Alliance to Accelerate Innovative Formulation Development

Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. ("Sanyou Biopharmaceuticals") and TransRecoBio (Wenzhou) Biotechnology Co., Ltd. ("TransRecoBio") officially...

May 14, 2025 | News

Altaris Unites WuXi and Minaris Assets to Launch Minaris Advanced Therapies as Global Cell Therapy CDMO Powerhouse

Through strategic acquisitions made by New York–based investment firm Altaris, Minaris Regenerative Medicine and the U.S. and U.K. operations of WuXi...

May 08, 2025 | News

Genezen to Manufacture Lentiviral Vector for Optieum’s CAR-T Therapy Targeting Glioblastoma

Genezen, a leading viral vector Contract Development and Manufacturing Organization (CDMO), and Optieum Biotechnologies, Inc. (Optieum), a preclinical stag...

May 06, 2025 | News

PCI Pharma Services Acquires Ajinomoto Althea’s Altair to Build Global Powerhouse in Aseptic Filling and Advanced Drug Delivery

PCI Pharma Services ("PCI") is pleased to announce the launch of Ajinomoto Althea, the world's leading contract research and manufacturing organi...

May 05, 2025 | News

Stay Connected